Toll-like receptor agonists have hit another setback with the Phase II failure of Idera's IMO-2055, but these immunotherapies may still make a comeback if appropriate combinations with vaccine ...
Dysregulation of the immune system contributes to the pathogenesis of neuropsychiatric disorders including schizophrenia. Here, we demonstrated that toll-like receptor (TLR)-2, a family of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results